-
Mashup Score: 32Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens - PubMed - 10 hour(s) ago
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure is the loss or downregulation of tumor antigen expression, yet strategies to modulate cell surface levels of CAR T cell targets remai …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet
-
Mashup Score: 31
Teclistamab is an anti-CD3xBCMA bispecific antibody approved for use in relapsed/refractory multiple myeloma (MM). We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the U.S. MM Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: https://t.co/czDaJ7PMjb. #mmsm https://t.co/43pzB17GbE
-
-
Mashup Score: 35
Not available.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Case report of the use of teclistamab for treatment of relapsed/refractory #POEMS syndrome producing a durable biochemical & radiographic remission lasting past drug discontinuation & without any unanticipated toxicities: https://t.co/5V3uHyMjpX. #mmsm https://t.co/lQUl0ZHZGv
-
-
Mashup Score: 15Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's Macroglobulinemia - PubMed - 3 day(s) ago
Data from our prospectively maintained multicenter database revealed that 8.6% and 3.4% of symptomatic patients with WM developed a SPM and disease transformation, respectively, over a median follow-up of 5.3 years.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Study of pts w/ symptomatic #Waldenström macroglobulinemia finds cumulative SPM incidence 4.0% & 7.2% @ 5 & 10 yrs; transformation to high-grade NHL accounting for death from WM or other cause @ 5 & 10 yrs was 2.1% & 3.4%: https://t.co/MjDzOdxTNP. #mmsm https://t.co/00E1jHZEil
-
-
Mashup Score: 22From CyBorD to Dara-CyBorD: ASCT Utilization Trends in AL Amyloidosis, A 15-Year Analysis - PubMed - 4 day(s) ago
This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for AL amyloidosis at Mayo Clinic (2010-2024). We aimed to assess ASCT utilization trends, factors influencing practice changes, and current indications amid newer therapies. 441 ASCTs were divided into Coho …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Analysis of ASCT & AL #amyloidosis @ Mayo (2010-2024) finds decrease in utilization; recent transplants mainly in pts w/ suboptimal responses, relapsed/refractory dz, lymphoplasmacytic clones or high BM PCs (MM phenotype): https://t.co/PoGFpxSPi8. #mmsm https://t.co/5NN4Guwply
-
-
Mashup Score: 0Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era - PubMed - 18 day(s) ago
Multiple myeloma (MM) derives from the clonal proliferation of plasma cells, primarily residing in the bone marrow. However, MM cells can disseminate systemically, leading to osseous or soft tissue extramedullary disease (EMM) or plasma cell leukemia (PCL). The presence of EMM or PCL has historicall …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Patients w/ extramedullary myeloma (EMM) @ dx or w/ solitary plasmacytoma progression have median OS 7.5 years; worse prognosis if w/ primary or secondary PCL & secondary EMM, high R-ISS, chromosome abnormalities, hi LDH: https://t.co/IjS0BTpArh. #mmsm https://t.co/f6ZMAsvLej
-
-
Mashup Score: 17Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma - PubMed - 19 day(s) ago
BackgroundMultiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical risk categories. Previous research has indicated that the absence of a normal plasma cell signature in MG …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Polyclonal plasma cell (PolyPC) signature may be a key indicator for predicting progression of MGUS to myeloma; sensitivity and specificity were 70% (28/40) and 81.7% (273/334): https://t.co/rx9rc8ydZp. #mmsm https://t.co/41C5RdqVrS
-
-
Mashup Score: 1
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski / cancer, Emiko Sakaida, Kazumoto Shibuya, Marie Morooka, MM, Moeko Ogushi, Myeloma, Myeloma
Source: oncodaily.comCategories: General Medicine NewsTweet-
RT @oncodaily: Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski (@Myeloma_Doc) @MDAndersonNews https://t.co/0HFoyDer00…
-
-
Mashup Score: 32Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series - PubMed - 20 day(s) ago
Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Daratumumab- and elotuzumab-based treatments for refractory #POEMS syndrome -> 1 hematologic (8%), 7 VEGF (54%), 2 neurologic (15%) and 8 generalized clinical responses (62%); median time to next treatment was 11 months: https://t.co/Vj0B47qaQq. #mmsm https://t.co/BCd3qEPngb
-
-
Mashup Score: 20
Not available.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
#Myeloma Paper of the Day: Quantitative multiparametric whole-body magnetic resonance imaging may be a useful part of our toolkit to help discriminate between smoldering and active myeloma though variability limits standalone use: https://t.co/JPOFAZNKDv. #mmsm https://t.co/pfB2NqnV0T
-
#Myeloma Paper of the Day: BCMA is a highly short-lived protein that undergoes K48-linked polyubiquitylation at plasma membrane & carfilzomib enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and refractory myeloma cells: https://t.co/9GBmjv0sa0. #mmsm https://t.co/KpTnmC11lp